Skip to content
The Intraday
Pulse

Briefings

Morning BriefOvernight tape and the setup for the openMid-Morning UpdateWhat changed after the opening bell

Markets

Market DashboardTape, movers, watchlist, and cross-asset contextPre-Market SheetOvernight setup, futures, and early moversGlobal SessionsInternational clocks and index performanceInsider ActivityLatest reported executive transactions

CRL Research

Price ChartTechnical charting and drawing workspaceFundamentals ChartCompare financial metrics across timeCompany OverviewA visual snapshot of company performanceFinancial StatementsPrice, filings, key statistics, and news

Newsletter

Morning Production ReportRanked stories, charts, and newsletter readiness

Financial Statements

Explore

Markets, briefings, and company research

CRL
Pulse

Briefings

MorningMid-Morning

Markets

DashboardPre-MarketGlobalInsiders

CRL Research

ChartFundamentalsOverviewFinancials

Newsletter

Morning Report

Newsletter operations and account tools are available from your profile menu after sign-in.

Charles River Laboratories International, Inc.

CRL
$265.51
+$4.79 (1.84%)+1.84%
Closed

Charles River Labs beats Q2 2026 estimates, raises 2026 guidance and announces Eli Lilly TuneLab AI drug discovery collaboration

Loading chart...
IndexN/A
Market Cap12.79B
Enterprise Value12.95B
Income$0.03B
Sales$0.98B
Employees18,700
P/E26.82
P/S2.51
P/B3.19
P/C19.47
EV/EBITDA31.51
EV/Sales9.69
EPS (ttm)9.90
Earnings2025-11-05
Gross Margin32.28%
Oper. Margin7.59%
Profit Margin2.59%
Volume1.31M
Shs Outstand0.05B
Change1.84%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTD8.54%
Perf Year34.37%
Perf 3Y-7.12%
Perf 5Y-21.22%
Perf 10Y189.84%
IPO2000-06-23
Income Statement by fiscal year, newest to oldest
MetricFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Revenue$4.05B$4.13B$3.98B$3.54B$2.92B$2.62B$2.27B$1.86B
Cost of Revenue$2.72B$2.63B$2.51B$2.21B$1.85B$1.66B$1.43B$1.16B
Gross Profit$1.33B$1.50B$1.46B$1.33B$1.07B$958.31M$840.07M$700.92M
Gross Margin32.88%36.39%36.79%37.70%36.72%36.56%37.07%37.73%
Operating Expenses$1.10B$885.29M$811.68M$744.78M$640.81M$607.16M$508.68M$412.64M
Operating Income$227.35M$617.26M$650.98M$589.86M$432.73M$351.15M$331.38M$288.28M
Operating Margin5.61%14.95%16.37%16.66%14.80%13.40%14.62%15.52%
Net Income$10.30M$474.62M$486.23M$390.98M$364.30M$252.02M$226.37M$123.36M
Net Margin0.25%11.49%12.23%11.04%12.46%9.61%9.99%6.64%
EPS (Basic)$0.20$9.27$9.57$7.77$7.35$5.17$4.72$2.60
EBITDA$581.14M$1.03B$986.15M$820.16M$768.47M$563.06M$507.23M$457.89M
Stock Option Compensation Expense$69.89M$72.05M$73.62M$71.47M$56.34M$57.27M$47.35M$44.00M
Price To Earnings Ratio928.9025.5222.7748.4733.9829.5423.9742.13
Price To Sales RatioN/AN/AN/AN/AN/AN/AN/AN/A
Shares OutstandingN/AN/AN/AN/AN/AN/AN/AN/A
Market Capitalization$9.56B$12.11B$11.07B$18.95B$12.38B$7.44B$5.43B$5.20B
Balance Sheet by fiscal year, newest to oldest
MetricFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Cash & Short Term InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Short Term ReceivablesN/AN/AN/AN/AN/AN/AN/AN/A
InventoriesN/AN/AN/AN/AN/AN/AN/AN/A
Other Current AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Total Current AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Net Property, Plant & EquipmentN/AN/AN/AN/AN/AN/AN/AN/A
Total Investments and AdvancesN/AN/AN/AN/AN/AN/AN/AN/A
Long-Term Note ReceivableN/AN/AN/AN/AN/AN/AN/AN/A
Intangible AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Deferred Tax AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Other AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Total Assets$7.53B$8.20B$7.60B$7.02B$5.49B$4.69B$3.86B$2.93B
Short Term Debt Incl. Current Port. of LT DebtN/AN/AN/AN/AN/AN/AN/AN/A
Accounts PayableN/AN/AN/AN/AN/AN/AN/AN/A
Income Tax PayableN/AN/AN/AN/AN/AN/AN/AN/A
Other Current LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Total Current LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Provision for Risks ChargesN/AN/AN/AN/AN/AN/AN/AN/A
Deferred Tax LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Other LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Total Liabilities$4.02B$4.54B$4.58B$4.43B$3.35B$3.03B$2.52B$1.87B
Non-Equity ReservesN/AN/AN/AN/AN/AN/AN/AN/A
Preferred Stock - Carrying ValueN/AN/AN/AN/AN/AN/AN/AN/A
Common EquityN/AN/AN/AN/AN/AN/AN/AN/A
Total Shareholders Equity$3.46B$3.60B$2.98B$2.53B$2.11B$1.63B$1.32B$1.05B
Accumulated Minority InterestN/AN/AN/AN/AN/AN/AN/AN/A
Total Equity$3.46B$3.60B$2.98B$2.53B$2.11B$1.63B$1.32B$1.05B
Total Liabilities & Stockholders Equity$7.53B$8.20B$7.60B$7.02B$5.49B$4.69B$3.86B$2.93B
Book Value Per Share$68.28$71.43$59.50$51.54$43.26$34.20$27.91$22.41
Tangible Book Value Per Share$-1.21$-5.86$-15.38$-23.48$-9.14$-11.56$-10.84$-2.33
Full-Time EmployeesN/AN/AN/AN/AN/AN/AN/AN/A
Price to Book RatioN/AN/AN/AN/AN/AN/AN/AN/A
Return on Assets0.14%5.79%6.40%5.57%6.63%5.37%5.87%4.21%
Return on Equity0.30%13.20%16.34%15.42%17.23%15.42%17.18%11.80%
Return on Invested Capital0.95%7.14%7.91%8.12%7.48%7.26%8.02%4.88%
Quick Ratio1.131.161.081.041.211.211.381.54
Current Ratio1.411.521.321.231.431.441.611.78
Cash Flow by fiscal year, newest to oldest
MetricFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Net Income$10.30M$474.62M$486.23M$390.98M$364.30M$252.02M$226.37M$123.36M
Depreciation$361.74M$314.12M$303.87M$265.54M$234.92M$198.09M$161.78M$131.16M
Other Funds (Non Cash)N/AN/AN/AN/AN/AN/AN/AN/A
Funds from OperationsN/AN/AN/AN/AN/AN/AN/AN/A
Extraordinary ItemN/AN/AN/AN/AN/AN/AN/AN/A
Changes in Working CapitalN/AN/AN/AN/AN/AN/AN/AN/A
Income Taxes PayableN/AN/AN/AN/AN/AN/AN/AN/A
Cash from Operating Activities$734.58M$683.90M$619.64M$760.80M$546.58M$480.94M$441.14M$316.26M
Capital Expenditures$232.97M$318.53M$324.73M$228.77M$166.56M$140.51M$140.05M$82.43M
Net Assets From AcquisitionsN/AN/AN/AN/AN/AN/AN/AN/A
Sale of Fixed Assets and BusinessesN/AN/AN/AN/AN/AN/AN/AN/A
Purchase or Sale of InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Purchase of InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Sale Or Maturity of InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Other UsesN/AN/AN/AN/AN/AN/AN/AN/A
Other SourcesN/AN/AN/AN/AN/AN/AN/AN/A
Cash from Investing ActivitiesN/AN/AN/AN/AN/AN/AN/AN/A
Cash Dividends Paid$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Change in Capital StockN/AN/AN/AN/AN/AN/AN/AN/A
Repurchase of Common Pref Stock$119.17M$24.16M$38.65M$40.71M$23.98M$18.09M$13.85M$106.91M
Sale of Common Pref StockN/AN/AN/AN/AN/AN/AN/AN/A
Proceeds from Stock OptionsN/AN/AN/AN/AN/AN/AN/AN/A
Issuance or Reduction of Debt, NetN/AN/AN/AN/AN/AN/AN/AN/A
Change in Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Issuance of Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Reduction of Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Net Financing Active Other Cash FlowN/AN/AN/AN/AN/AN/AN/AN/A
Other Financing Activities UsesN/AN/AN/AN/AN/AN/AN/AN/A
Cash from Financing ActivitiesN/AN/AN/AN/AN/AN/AN/AN/A
Exchange Rate EffectN/AN/AN/AN/AN/AN/AN/AN/A
Net Change in CashN/AN/AN/AN/AN/AN/AN/AN/A
Free Cash Flow$501.61M$365.37M$294.91M$532.03M$380.01M$340.42M$301.09M$233.83M
Preferred Dividends (Cash Flow)N/AN/AN/AN/AN/AN/AN/AN/A
Price to Free Cash FlowN/AN/AN/AN/AN/AN/AN/AN/A

Company coverage

Latest news

20 stories
Yesterday · 7:59AMHere Are Thursday’s Top Wall Street Analyst Research Calls: AppLovin, Charles River, Global Payments, HubSpot, Insulet Corporation, Roper Technologies, Sabra Health Care, Western Digital, Zillow Group, and More247wallst.com ↗Yesterday · 7:05AMCharles River Laboratories International Q2 Earnings Call Highlightsmarketbeat.com ↗Aug 5 · 2:10PMCharles River Laboratories International, Inc. (CRL) Q2 2026 Earnings Call Transcriptseekingalpha.com ↗Aug 5 · 11:56AMCRL Q2 Earnings and Revenues Top, '26 View Up, Stock Up in Pre-Marketzacks.com ↗Aug 5 · 10:41AMHas Charles River Laboratories International (CRL) Outpaced Other Medical Stocks This Year?zacks.com ↗Aug 5 · 10:38AMCharles River: Near-Term Inflection But Long-Term Riskseekingalpha.com ↗Aug 5 · 10:31AMCharles River (CRL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimateszacks.com ↗Aug 5 · 10:01AMCharles River Laboratories (CRL) Q2 Earnings and Revenues Surpass Estimateszacks.com ↗
Show 12 more stories↓
Aug 5 · 7:38AMCharles River lifts profit forecast on improving biotech demandreuters.com ↗Aug 5 · 7:00AMCharles River Laboratories Announces Second-Quarter 2026 Resultsbusinesswire.com ↗Aug 4 · 3:43AMCalifornia State Teachers Retirement System Boosts Holdings in Charles River Laboratories International, Inc. $CRLdefenseworld.net ↗Aug 1 · 4:05AMAvidity Partners Management LP Buys New Shares in Charles River Laboratories International, Inc. $CRLdefenseworld.net ↗Jul 30 · 2:31PMCharles River Prepares to Report Q2 Earnings: What's in Store?zacks.com ↗Jul 29 · 11:01AMCharles River Laboratories (CRL) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Releasezacks.com ↗Jul 27 · 4:01AMEpoch Investment Partners Inc. Sells 21,131 Shares of Charles River Laboratories International, Inc. $CRLdefenseworld.net ↗Jul 23 · 6:41PMCharles River Laboratories International Inc (CRL) Stock Up 4.8% but GF Value Says Overvalued -- GF Score: 70/100gurufocus.com ↗Jul 21 · 1:32PMIXJ vs. RSPH: Which Healthcare ETF Is the Better Buy?fool.com ↗Jul 21 · 4:03AMFifth Third Bancorp Buys 6,002 Shares of Charles River Laboratories International, Inc. $CRLdefenseworld.net ↗Jul 17 · 1:01PMWhat Makes Charles River Laboratories (CRL) a Strong Momentum Stock: Buy Now?zacks.com ↗Jul 14 · 1:10PMWill Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?zacks.com ↗

Insider Trading

View All
Insider
Type
Shares
Price
Value
Date
Michael Knell
Sell
6.6K
$260.00
$1.7M
Aug 6, 26
Victoria Creamer
Sell
4.2K
$260.00
$1.1M
Aug 6, 26
Parisotto Shannon M
Sell
5.0K
$263.00
$1.3M
Aug 5, 26
Parisotto Shannon M
Sell
5.0K
$263.00
$1.3M
Aug 5, 26
FOSTER JAMES C
Sell
75.0K
$225.00
$16.9M
Jun 29, 26

Company

CEO: Birgit GirshickEmployees: 19700www.criver.com
About the company↓

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Discover more

You may be interested in
AMZN

Amazon.com Inc

$272.26

↓ 0.14%
ORCL

Oracle Corp

$143.42

↓ 0.67%
ABX

Abacus Global Management Inc

$10.40

↓ 1.52%
IBM

IBM Corp

$233.43

↓ 1.06%
ADBE

Adobe Inc

$260.24

↑ 0.35%
MA

Mastercard Inc

$575.95

↑ 0.96%
CRM

Salesforce Inc

$186.77

↓ 3.22%
META

Meta Platforms Inc

$589.90

↑ 0.19%
INTC

Intel Corp

$99.81

↓ 1.24%
AMD

Advanced Micro Devices

$489.28

↑ 1.50%
DIS

Walt Disney Co

$104.67

↑ 2.86%
TSLA

Tesla Inc

$319.53

↓ 0.63%
The Intraday

© 2026 The Intraday. All rights reserved.

Market data may be delayedFor informational purposes onlyFMP · Massive · SEC